|
1
|
Pike MC, Krailo MD, Henderson BE,
Casagrande JT and Hoel DG: ‘Hormonal’ risk factors, ‘breast tissue
age’ and the age-incidence of breast cancer. Nature. 303:767–770.
1983.
|
|
2
|
Santen RJ, Boyd NF, Chlebowski RT, et al:
Critical assessment of new risk factors for breast cancer:
considerations for development of an improved risk prediction
model. Endocr Relat Cancer. 14:169–187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Missmer SA, Eliassen AH, Barbieri RL and
Hankinson SE: Endogenous estrogen, androgen, and progesterone
concentrations and breast cancer risk among postmenopausal women. J
Natl Cancer Inst. 96:1856–1865. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russo J, Hasan Lareef M, Balogh G, Guo S
and Russo IH: Estrogen and its metabolites are carcinogenic agents
in human breast epithelial cells. J Steroid Biochem Mol Biol.
87:1–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodriguez C, Patel AV, Calle EE, Jacob EJ
and Thun MJ: Estrogen replacement therapy and ovarian cancer
mortality in a large prospective study of US women. JAMA.
285:1460–1465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baldwin WS, Curtis SW, Cauthen CA,
Risinger JI, Korach KS and Barrett JC: BG-1 ovarian cell line: an
alternative model for examining estrogen-dependent growth in vitro.
In Vitro Cell Dev Biol Anim. 34:649–654. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giacalone PL, Daures JP, Ouafik L, Martin
PM, Laffargue F and Maudelonde T: Steroids and adrenomedullin
growth patterns in human ovarian cancer cells:
estrogenic-regulation assay. Gynecol Oncol. 91:651–656. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grady D, Gebretsadik T, Kerlikowske K,
Ernster V and Petitti D: Hormone replacement therapy and
endometrial cancer risk: a meta-analysis. Obstet Gynecol.
85:304–313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chung SH, Franceschi S and Lambert PF:
Estrogen and ERalpha: culprits in cervical cancer? Trends
Endocrinol Metab. 21:504–511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soto AM and Sonnenschein C: Environmental
causes of cancer: endocrine disruptors as carcinogens. Nat Rev
Endocrinol. 6:363–370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Crisp TM, Clegg ED, Cooper RL, et al:
Environmental endocrine disruption: an effects assessment and
analysis. Environ Health Perspect. 106(Suppl 1): 11–56. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cabaravdic M: [Xenoestrogen effects of
chemical compounds: influence on the breast cancer]. Med Arh.
60:97–100. 2006.(In Bosnian).
|
|
13
|
Lee HR, Hwang KA, Park MA, Yi BR, Jeung EB
and Choi KC: Treatment with bisphenol A and methoxychlor results in
the growth of human breast cancer cells and alteration of the
expression of cell cycle-related genes, cyclin D1 and p21, via an
estrogen receptor-dependent signaling pathway. Int J Mol Med.
29:883–890. 2012.
|
|
14
|
Park MA, Hwang KA and Choi KC: Diverse
animal models to examine potential role(s) and mechanism of
endocrine disrupting chemicals on the tumor progression and
prevention: do they have tumorigenic or anti-tumorigenic property?
Lab Anim Res. 27:265–273. 2011. View Article : Google Scholar
|
|
15
|
Park MA, Hwang KA, Lee HR, Yi BR, Jeung EB
and Choi KC: Cell growth of BG-1 ovarian cancer cells is promoted
by di-n-butyl phthalate and hexabromocyclododecane via upregulation
of the cyclin D and cyclin-dependent kinase-4 genes. Mol Med Rep.
5:761–766. 2012.PubMed/NCBI
|
|
16
|
Wolstenholme JT, Rissman EF and Connelly
JJ: The role of Bisphenol A in shaping the brain, epigenome and
behavior. Horm Behav. 59:296–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee HR, Kim TH and Choi KC: Treatment with
bisphenol A leads to the promotion of human breast cancer cells and
alteration of cell cycle-related gene expression, cyclin E and p27.
J Biomed Res. 12:215–233. 2011.
|
|
18
|
Brede C, Fjeldal P, Skjevrak I and
Herikstad H: Increased migration levels of bisphenol A from
polycarbonate baby bottles after dishwashing, boiling and brushing.
Food Addit Contam. 20:684–689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joskow R, Barr DB, Barr JR, Calafat AM,
Needham LL and Rubin C: Exposure to bisphenol A from bis-glycidyl
dimethacrylate-based dental sealants. J Am Dent Assoc. 137:353–362.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang JH, Kito K and Kondo F: Factors
influencing the migration of bisphenol A from cans. J Food Prot.
66:1444–1447. 2003.PubMed/NCBI
|
|
21
|
Maffini MV, Rubin BS, Sonnenschein C and
Soto AM: Endocrine disruptors and reproductive health: the case of
bisphenol-A. Mol Cell Endocrinol. 254–255:179–186. 2006.PubMed/NCBI
|
|
22
|
Fernandez SV and Russo J: Estrogen and
xenoestrogens in breast cancer. Toxicol Pathol. 38:110–122. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prins GS, Birch L, Tang WY and Ho SM:
Developmental estrogen exposures predispose to prostate
carcinogenesis with aging. Reprod Toxicol. 23:374–382. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vandenberg LN, Maffini MV, Sonnenschein C,
Rubin BS and Soto AM: Bisphenol-A and the great divide: a review of
controversies in the field of endocrine disruption. Endocr Rev.
30:75–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bai W, Oliveros-Saunders B, Wang Q,
Acevedo-Duncan ME and Nicosia SV: Estrogen stimulation of ovarian
surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim.
36:657–666. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi KC, Kang SK, Tai CJ, Auersperg N and
Leung PC: Estradiol up-regulates antiapoptotic Bcl-2 messenger
ribonucleic acid and protein in tumorigenic ovarian surface
epithelium cells. Endocrinology. 142:2351–2360. 2001.PubMed/NCBI
|
|
27
|
Lindgren P, Backstrom T, Mahlck CG,
Ridderheim M and Cajander S: Steroid receptors and hormones in
relation to cell proliferation and apoptosis in poorly
differentiated epithelial ovarian tumors. Int J Oncol. 19:31–38.
2001.PubMed/NCBI
|
|
28
|
Ptak A and Gregoraszczuk EL: Bisphenol A
induces leptin receptor expression, creating more binding sites for
leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt
signalling pathways in human ovarian cancer cell. Toxicol Lett.
210:332–337. 2012. View Article : Google Scholar
|
|
29
|
Ptak A, Wrobel A and Gregoraszczuk EL:
Effect of bisphenol-A on the expression of selected genes involved
in cell cycle and apoptosis in the OVCAR-3 cell line. Toxicol Lett.
202:30–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sirtori CR, Arnoldi A and Johnson SK:
Phytoestrogens: end of a tale? Ann Med. 37:423–438. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mense SM, Hei TK, Ganju RK and Bhat HK:
Phytoestrogens and breast cancer prevention: possible mechanisms of
action. Environ Health Perspect. 116:426–433. 2008.PubMed/NCBI
|
|
32
|
Ravindranath MH, Muthugounder S, Presser N
and Viswanathan S: Anticancer therapeutic potential of soy
isoflavone, genistein. Adv Exp Med Biol. 546:121–165. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li HQ, Luo Y and Qiao CH: The mechanisms
of anticancer agents by genistein and synthetic derivatives of
isoflavone. Mini Rev Med Chem. 12:350–362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB
and Choi KC: Antitumor therapeutic effects of cytosine deaminase
and interferon-beta against endometrial cancer cells using
genetically engineered stem cells in vitro. Anticancer Res.
31:2853–2861. 2011.
|
|
35
|
Yi BR, O SN, Kang NH, et al: Genetically
engineered stem cells expressing cytosine deaminase and
interferon-beta migrate to human lung cancer cells and have
potentially therapeutic anti-tumor effects. Int J Oncol.
39:833–839. 2011.PubMed/NCBI
|
|
36
|
Kim KY, Yi BR, Lee HR, et al: Stem cells
with fused gene expression of cytosine deaminase and
interferon-beta migrate to human gastric cancer cells and result in
synergistic growth inhibition for potential therapeutic use. Int J
Oncol. 40:1097–1104. 2012.
|
|
37
|
Kang NH, Yi BR, Lim SY, et al: Human
amniotic membrane-derived epithelial stem cells display anticancer
activity in BALB/c female nude mice bearing disseminated breast
cancer xenografts. Int J Oncol. 40:2022–2028. 2012.
|
|
38
|
Kang NH, Hwang KA, Yi BR, et al: Human
amniotic fluid-derived stem cells expressing cytosine deaminase and
thymidine kinase inhibits the growth of breast cancer cells in
cellular and xenograft mouse models. Cancer Gene Ther. 19:412–419.
2012. View Article : Google Scholar
|
|
39
|
Krell J, Januszewski A, Yan K and Palmieri
C: Role of fulvestrant in the management of postmenopausal breast
cancer. Expert Rev Anticancer Ther. 11:1641–1652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kansra S, Yamagata S, Sneade L, Foster L
and Ben-Jonathan N: Differential effects of estrogen receptor
antagonists on pituitary lactotroph proliferation and prolactin
release. Mol Cell Endocrinol. 239:27–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pelekanou V and Leclercq G: Recent
insights into the effect of natural and environmental estrogens on
mammary development and carcinogenesis. Int J Dev Biol. 55:869–878.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moghadam SJ, Hanks AM and Keyomarsi K:
Breaking the cycle: An insight into the role of ERalpha in
eukaryotic cell cycles. J Carcinog. 10:252011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Heldring N, Pike A, Andersson S, et al:
Estrogen receptors: how do they signal and what are their targets.
Physiol Rev. 87:905–931. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dos Santos E, Dieudonne MN, Leneveu MC, et
al: Effects of 17beta-estradiol on preadipocyte proliferation in
human adipose tissue: involvement of IGF1-R signaling. Horm Metab
Res. 42:514–520. 2010.PubMed/NCBI
|
|
45
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Foster JS and Wimalasena J: Estrogen
regulates activity of cyclin-dependent kinases and retinoblastoma
protein phosphorylation in breast cancer cells. Mol Endocrinol.
10:488–498. 1996.PubMed/NCBI
|
|
47
|
Konduri SD, Medisetty R, Liu W, et al:
Mechanisms of estrogen receptor antagonism toward p53 and its
implications in breast cancer therapeutic response and stem cell
regulation. Proc Natl Acad Sci USA. 107:15081–15086. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J and McMurray RW: Effects of estrogen
receptor subtype-selective agonists on autoimmune disease in
lupus-prone NZB/NZW F1 mouse model. Clin Immunol. 123:219–226.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hwang KA, Park SH, Yi BR and Choi KC: Gene
alterations of ovarian cancer cells expressing estrogen receptors
by estrogen and bisphenol a using microarray analysis. Lab Anim
Res. 27:99–107. 2011. View Article : Google Scholar
|
